Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medivation, Inc.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.